10391-08-9 Usage
Description
Macrocalin A, a natural product derived from the plant Macrocalyx longiflorus, is a member of the diterpenoid alkaloid family. It is characterized by a complex ring system with multiple functional groups that contribute to its biological activity. macrocalin A has demonstrated potential anti-inflammatory and analgesic properties, positioning it as a promising candidate for the development of new therapeutic agents to treat various inflammatory conditions.
Uses
Used in Pharmaceutical Industry:
Macrocalin A is used as a therapeutic agent for its potential anti-inflammatory and analgesic properties, targeting the treatment of various inflammatory conditions. Its complex chemical structure and multiple functional groups are believed to contribute to its biological activity, making it a valuable compound for further research and development in medicine.
Further research is necessary to fully understand the mechanism of action and explore additional potential applications of macrocalin A in the medical field. As our understanding of this compound grows, it may lead to the development of novel treatments for a range of inflammatory diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 10391-08-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,3,9 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 10391-08:
(7*1)+(6*0)+(5*3)+(4*9)+(3*1)+(2*0)+(1*8)=69
69 % 10 = 9
So 10391-08-9 is a valid CAS Registry Number.
InChI:InChI=1/C20H26O5/c1-10-11-4-5-12-19(8-11,15(10)21)17(23)25-13-6-7-18(2,3)14-16(22)24-9-20(12,13)14/h11-14,16,22H,1,4-9H2,2-3H3
10391-08-9Relevant articles and documents
Divergent Total Syntheses of Enmein-Type Natural Products: (?)-Enmein, (?)-Isodocarpin, and (?)-Sculponin R
Pan, Saiyong,Chen, Sicong,Dong, Guangbin
, p. 6333 - 6336 (2018)
Divergent total syntheses of the enmein-type natural products (?)-enmein, (?)-isodocarpin, and (?)-sculponin R have been achieved in a concise fashion. Key features of the strategy include 1) an efficient early-stage cage formation to control succeeding diastereoselectivity, 2) a one-pot acylation/akylation/lactonization to construct the C-ring and C8 quarternary center, 3) a reductive alkenylation approach to construct the enmain D/E rings and 4) a flexible route to allow divergent syntheses of three natural products.